Keywords: Actelion, First nine months 2011 financial results
Actelion posts 85.6 Swiss franc loss for first nine months of 2011
Article | 20 October 2011
Switzerland-based Actelion (ATLN: VX) recorded an operating loss of 85.6 million Swiss francs ($95.5 million) for the first nine months of 2011, compared ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
